Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome
- 10 April 2015
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (8) , 1291-1299
Abstract
Because of the possible interference of antiphospholipid antibodies (APL) with the phospholipid component of thromboplastin reagents, concerns have been raised about the validity of international normalized ratio (INR) testing to monitor anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome (APS). To investigate the reliability of the INR, we determined the INR using various prothrombin time (PT) assays and compared the results with those of a chromogenic factor X (CFX) assay. The study cohort consisted of 40 APS patients and 100 APL-negative patients who were on anticoagulant therapy for reasons other than APS. The agreement (i.e. the percentage of patients with a difference ≤0.5 INR units) between the PT-derived INR and CFX-derived INR equivalents was only moderate in both patient groups. The best agreement with CFX-derived INR equivalents was observed for the Thromborel S reagent in APS patients (69.1 %) and for Neoplastin Plus in APL-negative patients (72.0 %). Regarding the results for the point-of-care system CoaguChek XS, an agreement between the INR and the CFX-derived INR equivalent was less frequently observed in the APS patients (55.6 vs. 67.8 %; p = 0.050). When considering all 3058 pairs of INR tests within the international sensitivity index (ISI)-calibrated range of 1.5 to 4.5 s, we did not observe a higher variability of INR values in either the APS patient group or the subgroup of APS patients positive for lupus coagulants compared with the APL-negative controls. In conclusion, monitoring vitamin K antagonists (VKA) therapy with laboratory INR measurements seems to be suitable for the majority of APS patients.Keywords
This publication has 31 references indexed in Scilit:
- From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndromeThrombosis Research, 2013
- Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-AntagonistsThrombosis Research, 2012
- Guidelines on the investigation and management of antiphospholipid syndromeBritish Journal of Haematology, 2012
- Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?Clinical Chemistry and Laboratory Medicine (CCLM), 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administrationBlood Coagulation & Fibrinolysis, 2009
- Strongly Increased International Normalized Ratio with Recombinant Neoplastin R® Compared with Tissue Extract Neoplastin Plus® in Patients Initiating Oral Anticoagulant Therapy: Implications for Anticoagulation DosageClinical Chemistry, 2008
- Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapyBlood Coagulation & Fibrinolysis, 2008
- Phospholipid composition controls thromboplastin sensitivity to individual clotting factorsJournal of Thrombosis and Haemostasis, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006